Speaker Profile

___	__
	Biography Dr. Andrea Lausman is currently appointed as a Maternal-Fetal Medicine Specialist at St. Michael’s Hospital, in Toronto, Canada, where she is also the Deputy Chief of Obstetrics. She is an Assistant Professor at the University of Toronto. Her current clinical practice includes a focus on medical complications of pregnancy. She has a keen interest in caring for pregnant people with a variety of pre-existing conditions who are at risk of placental insufficiency and the development of fetal growth restriction. Her research interests are varied and include exploring diagnosis and treatment options for Iron Deficiency Anemia in Pregnancy, as well as continuing to contribute to the literature on Fetal Growth Restriction. Disclosure 1. I have a relationship with a for-profit and/or a not-for-profit organization to disclose: - Direct financial payments including receipt of honoraria: Pfizer, Seaford Pharmaceuticals 2. I do not intend to make therapeutic recommendations for medications that have not received regulatory approval (i.e. "off-label" use of medication).

Biography
Dr. Andrea Lausman is currently appointed as a Maternal-Fetal Medicine Specialist at St. Michael’s Hospital, in Toronto, Canada, where she is also the Deputy Chief of Obstetrics. She is an Assistant Professor at the University of Toronto. Her current clinical practice includes a focus on medical complications of pregnancy. She has a keen interest in caring for pregnant people with a variety of pre-existing conditions who are at risk of placental insufficiency and the development of fetal growth restriction. Her research interests are varied and include exploring diagnosis and treatment options for Iron Deficiency Anemia in Pregnancy, as well as continuing to contribute to the literature on Fetal Growth Restriction.
Disclosure
1. I have a relationship with a for-profit and/or a not-for-profit organization to disclose: - Direct financial payments including receipt of honoraria: Pfizer, Seaford Pharmaceuticals 2. I do not intend to make therapeutic recommendations for medications that have not received regulatory approval (i.e. "off-label" use of medication).